Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient

Journal of Hypertension

Volumn 30, Issue 12, 2012, Pages 2403-2409

  Gosse, Philippe ^a   Cremer, Antoine ^a   Vircoulon, Marion ^a   Coulon, Paul ^a   Jan, Emilie ^a   Papaioannou, Georgios ^a   Yeim, Sunthareth ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

cutoff; echocardiography; hypertension; left ventricular hypertrophy; regression

Indexed keywords

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DISEASE COURSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VASCULAR DISEASE;

EID: 84870251835     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283593029     Document Type: Article

References (22)

1. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005; 23:S27-S33.
2. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110:101-107.
4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
5. de Simone G, Izzo R, Chinali M, De Marco M, Casalnuovo G, Rozza F, et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension? Hypertension 2010; 56:99-104.
6. Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens 2010; 23:876-881.
7. Yasuno S, Ueshima K, Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial. J Hypertens 2009; 27:1705-1712.
8. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55:613-618.
9. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20:1251-1260.
10. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056-1062.
11. Nunez E, Arnett DK, Benjamin EJ, Liebson PR, Skelton TN, Taylor H, Andrew M. Optimal threshold value for left ventricular hypertrophy in blacks: the Atherosclerosis Risk in Communities study. Hypertension 2005; 45:58-63.
12. de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens 2005; 18:191-196.
13. Devereux RB, Agabiti-Rosei E, Dahlof B, Gosse P, Hahn RT, Okin PM, Roman MJ. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens 1996; 14:s95-s102.
14. Cipriano C, Gosse P, Bemurat L, Mas D, Lemetayer P, N'Tela G, Clementy J. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001; 14:524-529.
15. Devereux R, Dahlof B, Gerdts E, Boman K, Nieminen M, Papademetriou V. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the LIFE trial. Circulation 2004; 110:1456-1462.
16. Franz IW, Ketelhut R, Behr U, Tonnesmann U. Time course of reduction in left ventricular mass during long-term antihypertensive therapy. J Hum Hypertens 1994; 8:191-198.
17. Yurenev AP, Dyakonova EG, Novikov ID, Vitols AV, Pahl L, Haynemann G, et al. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Am J Hypertens. 1992; 5:182s-189s.
18. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
19. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
20. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
21. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 2006; 19:493-499.
22. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 2008; 21:464-470.